Stephen Mandel
Lone Pine Capital
Stephen Mandel Fate Therapeutics Inc stake
total: 304
Lone Pine Capital FATE trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Held since:
- 2020 Q4
- Held for:
- 4 quarters
- Latest activity:
- 2021 Q4
According to 2026 Q2 report, Stephen Mandel doesn't hold any Fate Therapeutics Inc (FATE) shares. To date, the estimated cost basis is nearly $81.11 for "buy" trades and estimated average "sell" price is $59.27. Lone Pine Capital first purchased FATE in 2020 Q4, initially acquiring 883,666 shares. Since the initial investment in Fate Therapeutics Inc (FATE), Lone Pine Capital has made 3 more transactions.
When did Stephen Mandel sell Fate Therapeutics Inc (FATE)?
Stephen Mandel sold off the entire Fate Therapeutics Inc (FATE) position in 2021 Q4.
When did Stephen Mandel buy Fate Therapeutics Inc (FATE)?
Stephen Mandel first invested in Fate Therapeutics Inc (FATE) in 2020 Q4 at the reported quarter-end price of $90.93 per share.
What's the cost basis of Lone Pine Capital's FATE stake?
The estimated cost basis for Fate Therapeutics Inc (FATE) stake is around $81.11 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $81.11
- Weighted AVG sell price:
- $59.27
Stephen Mandel's historical trades in Fate Therapeutics Inc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q4
|
0.00%
|
0
|
$59.27
|
|
-100% (-2,199,284)
|
-0.44%
|
|
2021 Q3
|
0.44%
|
2,199,284
|
$59.27
|
$130,352,000
|
+25.72% (+450,000)
|
+0.09%
|
|
2021 Q1
|
0.52%
|
1,749,284
|
$82.45
|
$144,228,000
|
+97.96% (+865,618)
|
+0.26%
|
|
2020 Q4
|
0.29%
|
$90.93
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.